|Dr. Ian E. Dixon M.A.I.C.D., M.B.A., MBA, Ph.D.||Founder, Technology Co-Founder, CEO MD & Director||361.79k||N/A||N/A|
|Dr. Gregor Lichtfuss M.Sc.||Co-Founder & Bus. Services Mang.||N/A||N/A||N/A|
|Mr. Johannes Muhl||Sr. VP of Fin.||N/A||N/A||N/A|
|Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP.||Company Sec.||N/A||N/A||1970|
Exopharm Limited develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. The company's technology includes LOAD technology platform that enables loading of active pharmaceutical ingredient (API) into exosomes; Ligand-based Exosome Affinity Purification (LEAP) technology that solves the critical bottleneck of exosome isolation and purification; MASTER CELL BANK to manufacture clinical-grade engineered exosomes; EVPS technology platform that allows specific molecules to be attached to the surface of exosomes to target them to selected tissues, organs, or cell types; EXORIA, a novel and proprietary dye that tags invisible exosomes to enhance tracking in experimental studies and laboratory analysis; and FORMULATION H to enable the stable storage and transport of exosome medicines. Exopharm Limited has research collaboration agreements with Astellas Institute for Regenerative Medicine. The company was incorporated in 2013 and is based in Camberwell, Australia.
Exopharm Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.